We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

IMproved PREdiction of Severe Sepsis in the Emergency Department (IMPRESSED)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 12, 2011
Last Update Posted: April 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Axis Shield Diagnostics Ltd
The purposes of this study is to determine whether Heparin Binding Protein (HBP) can be used as a marker of severe sepsis (including septic shock) in patients presenting to the emergency department with suspected infection.

Systemic Inflammatory Response Syndrome (SIRS) Sepsis Severe Sepsis Septic Shock

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.

Resource links provided by NLM:

Further study details as provided by Axis Shield Diagnostics Ltd:

Biospecimen Retention:   Samples With DNA
Plasma (LiHep and citrate)

Enrollment: 759
Study Start Date: March 2011
Study Completion Date: September 2015
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients presenting to emergency department with suspected infection

Inclusion Criteria:

  • Greater than or equal to 18 years
  • Suspected Infection
  • one or more SIRS criteria
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01392508

United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States
Universitetssjukhuset i Linkoping
Linkoping, Sweden
Skanes Universitetssjukhus i Lund
Lund, Sweden
Skanes Universitetssjukhuset i Malmo
Malmo, Sweden
Universitetssjukhuset i Orebro
Orebro, Sweden
Sponsors and Collaborators
Axis Shield Diagnostics Ltd
Principal Investigator: Adam Linder Skanes Universitetssjukhus I Lund, Sweden
Principal Investigator: Magnus Paulsson Skanes universitetssjukhuset i Malmo
Principal Investigator: Patrik Nyberg Universitetssjukhuset i Linkoping
Principal Investigator: Anna Lange-Jendeberg Universitetssjukhuset i Orebro
Principal Investigator: Ryan Arnold The Cooper Health System
  More Information

Responsible Party: Axis Shield Diagnostics Ltd
ClinicalTrials.gov Identifier: NCT01392508     History of Changes
Other Study ID Numbers: PEP-FMHBP-001
First Submitted: July 11, 2011
First Posted: July 12, 2011
Last Update Posted: April 14, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Shock, Septic
Systemic Inflammatory Response Syndrome
Disease Attributes
Pathologic Processes